April 20, 2017
Allergan and Target PharmaSolutions join to fight certain type of liver disease
Allergan will collaborate with Target PharmaSolutions on its five-year longitudinal observational study that looks at patients with nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).